TY  - JOUR
TI  - Primary cutaneous lymphomas and Coronavirus
disease-2019: A critical overview of primary cutaneous
lymphoma management in pandemic
AB  - Coronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some
risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group
of immune system neoplasms, which are subclassified as indolent and aggressive types according to their survival rates. PCL treatment
ranges from skin-based therapies to systemic treatments, of which immunosuppressive effects occur in some. During the COVID-19 pandemic,
patients with PCL should be protected from possible COVID-19 complications, and the optimal treatment should be provided to control the
disease taking into account the treatment-related risks. Therefore, recommendations about the management of patients with PCL during the
COVID-19 pandemic were overviewed in light of the literature. Topical treatments can generally be considered low-risk therapies and can be
continued without interruption. Phototherapy, skin radiotherapy, and total skin electron beam therapy increase the risk of COVID-19 exposure
due to hospital visits. Moderate-risk therapies like interferons, systemic retinoids, methotrexate, and systemic corticosteroids might be used
with caution. Advanced-stage patients with COVID-19 related comorbidity and who previously received immunosuppressive therapy should be
carefully evaluated. Biological agents and systemic chemotherapeutics, which are considered high-risk, should not be delayed when needed.
However, increasing intervals between treatments or switching to alternative therapies may be preferable in stabl
AU  - Onsun, Nahide
AU  - BİLGİÇ, Aslı
AU  - Sanli, Hatice
AU  - BAYRAMGÜRLER, Dilek
AU  - ÖRNEK, Sinem
AU  - YAZİC, Serkan
DO  - 10.4274/turkderm.galenos.2021.47817
PY  - 2022
JO  - Türkderm Türk deri hastalıkları ve frengi arşivi
VL  - 56
IS  - 1
SN  - 2717-6398
SP  - 1
EP  - 6
DB  - TRDizin
UR  - http://search/yayin/detay/519965
ER  -